GlassScriptPhysician profile
Alan Cadiz
NPI 1235287731
$1,367.85
in general payments reported to CMS, 2019-2025
23 companies · $234 in 2025
The $234 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $69.10 · 2021: $280 · 2022: $341 · 2023: $109 · 2024: $139 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $200.29 | 2021-2025 | Azstarys |
| Alk-Abello, INC | $174.73 | 2024-2025 | Odactra, Grastek, Neffy |
| Glaxosmithkline, LLC. | $128.89 | 2019-2023 | Bexsero |
| Cranial Technologies, INC | $106.61 | 2020-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $100.47 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $94.31 | 2019-2025 | |
| Pfizer INC. | $83.20 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.95 | 2021 | |
| Kaleo, INC. | $62.04 | 2019-2022 | |
| Seqirus USA INC | $56.77 | 2021-2022 | |
| Phadia US INC. | $44.77 | 2019-2024 | Immunocap |
| Merck Sharp & Dohme LLC | $39.72 | 2021-2024 | Gardasil, Gardasil 9, Vaxelis |
| Galderma Laboratories, L.P. | $29.52 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $24.48 | 2024 | |
| Sobi, INC | $19.85 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $19.43 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $19.37 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.96 | 2022 | |
| Shire North American Group INC | $17.32 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.36 | 2025 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $15.91 | 2025 | Zoryve |
| Tris Pharma INC | $14.91 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cadiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.